"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

The markets have succumbed to the headline pressure around inflation and tariffs, with all three of the major stock market indices trading in the red as of mid-morning. U.S. job growth slowed in ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability. Click for more on Capital Appreciation.

Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...